Natixis Advisors LLC Purchases 2,574 Shares of Avanos Medical, Inc. (NYSE:AVNS)

Natixis Advisors LLC lifted its stake in Avanos Medical, Inc. (NYSE:AVNS) by 13.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,452 shares of the company’s stock after purchasing an additional 2,574 shares during the period. Natixis Advisors LLC’s holdings in Avanos Medical were worth $515,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of AVNS. Tidal Investments LLC purchased a new stake in shares of Avanos Medical in the 1st quarter worth $439,000. Boston Partners purchased a new stake in shares of Avanos Medical in the 1st quarter worth $571,000. Azzad Asset Management Inc. ADV increased its stake in shares of Avanos Medical by 8.5% in the 2nd quarter. Azzad Asset Management Inc. ADV now owns 28,521 shares of the company’s stock worth $568,000 after purchasing an additional 2,223 shares in the last quarter. Paradice Investment Management LLC increased its stake in shares of Avanos Medical by 5.4% in the 2nd quarter. Paradice Investment Management LLC now owns 1,344,949 shares of the company’s stock worth $26,791,000 after purchasing an additional 69,389 shares in the last quarter. Finally, Quest Partners LLC purchased a new stake in shares of Avanos Medical in the 2nd quarter worth $444,000. 95.17% of the stock is currently owned by hedge funds and other institutional investors.

Avanos Medical Trading Down 0.1 %

Shares of AVNS stock opened at $19.14 on Friday. Avanos Medical, Inc. has a 52-week low of $17.39 and a 52-week high of $25.36. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.46 and a current ratio of 2.22. The firm has a market capitalization of $879.62 million, a PE ratio of 56.29 and a beta of 0.92. The stock has a fifty day simple moving average of $21.44 and a two-hundred day simple moving average of $21.54.

Analysts Set New Price Targets

Separately, StockNews.com lowered Avanos Medical from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 3rd.

Avanos Medical Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.